DANCANN Aktie

 

The following instruments on Boerse Frankfurt do have their last trading day on 23.01.2026 Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.01.2026 ISIN Name DK0063631999 DANCANN PHARMA DK 1 GB00BS457501 CORO ENERGY PLC LS-,005 US29873D1046 EUROBK ERGAS.ADR 1/2 NEW US7242495031 PIRAEUS F.HL.ADR NEW 2021 XS2462605671 TEL.EUROPE 22/UND. FLR...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL DANCANN PHARMA DK 1 DAN0 DK0063631999 BAW/UFN...

Instrument ID [22809442] (DAN0 - DK0063631999) suspended...

COPENHAGEN, Denmark, 13 January 2026 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) announced on 29 December 2025 that an extraordinary exercise period for a total of 1,224,993 warrants commenced as a result of the Company's application for a delisting. The last day of the extraordinary exercise period was yesterday, and no warrants have been exercised. No exercise of warrants As announced on 29 December 2025, a total of 1,224,993 outstanding warrants in the Company issued...

COPENHAGEN, Denmark, 8 January 2026 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) has on 7 January 2026 submitted to Spotlight Stock Market an application for a voluntary delisting of its shares from Spotlight Stock Market. Today, Spotlight Stock Market has approved the Company's application for a delisting, and consequently the Company's shares will be delisted from Spotlight Stock Market. Delisting application approved On 7 January 2026, the board of directors of the Company...

COPENHAGEN, Denmark, 7 January 2026 – DanCann Pharma A/S', CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) general meeting approved on 21 October 2025 that DanCann Pharma shall apply for a voluntary delisting of its shares from Spotlight Stock Market, and the Company has today submitted to Spotlight Stock Market an application for a voluntary delisting of its shares from Spotlight Stock Market. Application for delisting On 6 October 2025, the Company announced that the Company has resolved to apply for...

COPENHAGEN, Denmark, 6 January 2026 – DanCann Pharma A/S (CVR no. 39426005), a Danish medicinal cannabis company listed on Spotlight Stock Market under the ticker symbol SS: DANCAN (the “Company” or “DanCann Pharma”), today provides a New Year update from the Chairman of the Board of Directors, Carsten Trads, addressing recent strategic developments and the Company's current position following the divestment of CannGros ApS and the forthcoming delisting. On behalf of the Board of Directors, I would like to provide a New Year update following the recent strategic developments, including the...

COPENHAGEN, Denmark, 29 December 2025 – DanCann Pharma A/S', CVR-no. 39426005 (SS: DANCAN), a Danish company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) general meeting approved on 21 October 2025 that DanCann Pharma shall apply for a voluntary delisting of its shares from Spotlight Stock Market, and the application will be submitted to Spotlight Stock Market on 7 January 2026. For a total of 1,224,993 outstanding warrants in the Company, a delisting is deemed an “Exit” under the warrant terms which will entitle the warrant holders to exercise their warrants, and...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 17, 2025. STENOCARE A/S (“Stenocare” or the “Company”) announces that it has entered into a share purchase agreement with DanCann Pharma A/S (“DanCann”) to acquire 100% of the shares in CannGros ApS (“CannGros”), a wholly owned subsidiary of DanCann. With this agreement, Stenocare enters a new product category...

COPENHAGEN, Denmark, 17 November, 2025 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish company powered by cannabinoids listed on Spotlight Stock Market (“DanCann Pharma”), and StenoCare A/S, CVR-no. 39024705, a medical cannabis company listed on the Nasdaq First North Growth Market Denmark (“StenoCare”), announce that they have entered into a Share Purchase Agreement (the “Agreement” or the “SPA”). Under the Agreement, DanCann Pharma divests 100% of its shares in its wholly owned subsidiary, CannGros ApS, CVR-no. 39039451 (“CannGros”), to StenoCare, against issue of shares in...

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 17, 2025. STENOCARE A/S (“Stenocare” or the “Company”) announces that it has entered into a share purchase agreement with DanCann Pharma A/S (“DanCann”) to acquire 100% of the shares in CannGros ApS (“CannGros”), a wholly owned subsidiary of DanCann. With this agreement, Stenocare enters a new product category...

COPENHAGEN, Denmark, 27 October 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, today announces its financial results and operational highlights for the third quarter (Q3) of 2025. The period was marked by continued operational progress, strategic transformation, and key organizational changes. The Q3-2025 report is available as an attached document to this press release and at www.dancann.com. Summary: Group key figures Q3 2025 DKK '000 01/07/25– 01/07/24– 01/01/25– 01/01/24– 2024 Full year 30/...

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) On 21 October 2025 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company's address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposal to approve the board of directors' resolution of 6 October 2025 1. to apply for a voluntary delisting of the Company's shares from Spotlight Stock Market and adopt amendments to the Company's articles of association. (proposed by the...

COPENHAGEN, Denmark, 06 October 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, today publishes a letter from the Chairman of the Board. The letter provides additional context and elaboration on the Company's recent communications, outlining the current organizational developments, the voluntary delisting, and the strategic considerations guiding the Company's next steps. Dear Shareholders, On behalf of the Board of Directors of DanCann Pharma, I write to you at a time of important organizational change and strategic...

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Tuesday, 21 October 2025 at 09:00 am (CET) at DanCann Pharma A/S' address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the extraordinary general meeting is as follows: Proposal to approve the board of directors' resolution of 6 October 2025 1. to apply for a voluntary delisting of the Company's shares from Spotlight Stock Market and adopt amendments to the Company's articles of association. (proposed by the board...

COPENHAGEN, Denmark, 6 October 2025 – The board of directors of DanCann Pharma A/S (publ.) (“DanCann Pharma” or the “Company”) has today resolved to apply for a voluntary delisting of the Company's shares from Spotlight Stock Market. The resolution is conditional upon approval hereof by the general meeting of the Company. A notice convening an extraordinary general meeting will be published today by way of a separate press release. Background DanCann Pharma A/S was founded on 20 March 2018, and the Company's shares were admitted to trading on Spotlight Stock Market on 12 November 2020....

COPENHAGEN, Denmark, 25 August 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter (Q2) of 2025. The Q2-2025 report is available as an attached document to this press release and at www.dancann.com. Summary: Group Key Figures Q2-2025   DKK 1,000 01/04/25 01/04/24 01/01/25 – 30/06/25 01/01/24 – 30/06/24 – 30/06/25 – 30/06/24 Net Sales 1,182 3,856 1,427 4,551 EBITDA -2,236...

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides additional information regarding the bridge loan facility previously announced (the “Loan”). Terms of the Loan The Company has entered into a bridge loan agreement in the amount of DKK 2 million with a syndicate of ten (10) investors (collectively, the “Lenders”), including JEQ Capital AB, the Company's largest current shareholder. None of the Lenders are considered related parties to the Company under applicable regulations, and...

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the Company has received a conditional sales agreement regarding the sale of its production facility, Biotech Pharm1 (“BP1”), at a total consideration of EUR 1.25 million (DKK 9.32 million). In continuation of this, the Company has secured bridge financing for DKK 2 million to bridge liquidity until final sale of BP1, and to help propel its new Maturity2028 strategy. Conditional sales agreement for BP1 Since the Company's...

COPENHAGEN, Denmark, 23 May 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter (Q1) of 2025. The Q1-2025 report is available as an attached document to this press release and at www.dancann.com. Summary: Group Key Figures Q1-2025   +-------------+----------+-------------------+----------------+----------------+ |DKK 1,000 |01/01/25 |01/01/24 – 31/03/24|2024 (Full year)|2023 (Full year)| | |– 31/03/25| |...